![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2022
Herold, Michael; Hoster, Eva 
ORCID: https://orcid.org/0000-0002-0749-1389; Janssens, Ann; McCarthy, Helen; Tedeschi, Alessandra; Pocock, Chris; Rosta, Andras; Trněný, Marek; Nielsen, Tina G.; Knapp, Andrea; Hiddemann, Wolfgang und Marcus, Robert
(2022):
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial.
In: HemaSphere, Bd. 6, Nr. 3, e699
[PDF, 558kB]
ORCID: https://orcid.org/0000-0002-0749-1389; Janssens, Ann; McCarthy, Helen; Tedeschi, Alessandra; Pocock, Chris; Rosta, Andras; Trněný, Marek; Nielsen, Tina G.; Knapp, Andrea; Hiddemann, Wolfgang und Marcus, Robert
(2022):
Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial.
In: HemaSphere, Bd. 6, Nr. 3, e699
[PDF, 558kB]
2018
Trotman, Judith; Barrington, Sally F.; Belada, David; Meignan, Michel; MacEwan, Robert; Owen, Carolyn; Ptacnik, Vaclav; Rosta, Andras; Fingerle-Rowson, Günter R.; Zhu, Jiawen; Nielsen, Tina; Sahin, Deniz; Hiddemann, Wolfgang; Marcus, Robert E. und Davies, Andrew
(2018):
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
In: Lancet Oncology, Bd. 19, Nr. 11: S. 1530-1542